Going Beyond the Hard Endpoints “Quality of Life” May Be Dependent on Quality of Available Data∗ by Henry, Timothy D. & Gershlick, Anthony
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 1 9 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 9 . 0 2 0EDITORIAL COMMENTGoing Beyond the Hard Endpoints
“Quality of Life” May Be Dependent on
Quality of Available Data*Timothy D. Henry, MD,y Anthony Gershlick, MBBSzSEE PAGE 2104W e have made remarkable progress inthe treatment of ST-segment elevationmyocardial infarction (STEMI) over the
last 2 decades, mostly through the introduction
of acute percutaneous coronary intervention (PCI).
However, important issues remain, including how
we should manage the approximate 40% to 60% of
patients shown to have multivessel coronary artery
disease (MVCAD). To date, clinicians presented with
this common clinical problem have surprisingly
little robust evidence-based guidance on optimal
management. Until recently, most data came from
observational studies, registries, or selected patients
from randomized clinical trials designed to answer
different questions. Based on these limited (and con-
founded) data, PCI of a noninfarct vessel in hemody-
namically stable STEMI patients remains a Class 3
indication, meaning there is no evidence to support
the practice and it may be harmful, despite the recent
publication of a number of randomized trials showing
beneﬁt. In contrast, for STEMI patients with MVCAD
and cardiogenic shock, complete revascularization
has a Class 1 indication (1,2). It is perhaps this belief
that multivessel PCI in higher-risk patients leads to
better outcomes that potentially drives intervention-
alists to select sicker patients for this strategy; out-
comes are then determined by the patients being
sicker rather than as a result of the treatment strategy*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.itself, with the consequence that biased patient selec-
tion and biased patient outcomes affect the guide-
lines. Large randomized trials are underway to
determine whether multivessel PCI in the STEMI
setting improves morbidity and mortality.While we await their results, a different slant on
the potential value of a complete revascularization
strategy is provided by Jang et al. (3) in this issue of
the Journal. They report the inﬂuence of complete
versus culprit artery–only revascularization on qual-
ity of life (QoL) using data from 1,829 STEMI patients
enrolled in the TRIUMPH registry (The Translational
Research Investigating Underlying Disparities in
Acute Myocardial Infarction Patients’ Health Status)
at 24 U.S. hospitals from 2005 to 2008 (3).
What is actually meant by “QoL” and how impor-
tant it is as a metric in clinical trials remain the topic
of much debate. Although no one would doubt the
importance of hard clinical endpoints, once the pa-
tient has experienced an event-free survival, most are
seeking a good QoL. To some, this is spending time
with family and friends, but to a signiﬁcant propor-
tion, relief of their debilitating angina is central. They
value no longer having to stop unnecessarily whilst
their pain subsides. On the other side, at times the lay
public and healthcare professionals automatically
afford QoL a status well beyond any comprehension
of its deﬁnition, which can differ, and so it is of
utmost importance that we understand exactly what
is being measured. For example, QoL will be a
different measure in patients with intellectual difﬁ-
culties or where there are dependency issues.
In the current paper, the TRIUMPH study in-
vestigators used an established deﬁnition for symp-
tom relief, the Seattle Angina Questionnaire with
embedded angina frequency and QoL domains (scores
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2115range 0 to 100, with higher scores indicating less
angina and better QoL) (3). However, determining the
effect of any therapy or treatment strategy on QoL
depends clearly on the quality of the source data, and
herein lie 2 problems for this group—the overall lack
of certainty that multivessel PCI is beneﬁcial, and
some inherent weaknesses in data available to these
investigators.
In the 664 (36.3%) patients with multivessel dis-
ease, 251 (38%) had complete revascularization;
including 70 (28%) during the initial PCI, 161 (64%)
staged during the initial hospital setting, and 20
(8%) staged within the ﬁrst 6 weeks following
discharge. At 1-year post-STEMI, patients who un-
derwent complete revascularization had less angina
and improved QoL, but with no difference in mor-
tality (low at 3.6% vs. 3.4%), recurrent myocardial
infarction (3.5% vs. 1.4%), or repeat revascularization
(7.5% vs. 9.1%). “Severe angina” ($3 episodes/week)
was present in only 4.4% of patients with multivessel
PCI compared to 6.3% in culprit vessel–only patients.
The patients’ health status was measured by the
Seattle Angina Questionnaire at the time of STEMI
and 1 year later; however, one-third of data were
missing, and further, it is unclear whether “baseline”
reﬂected 1 week before STEMI, time of STEMI, or the
day after PCI (3). In addition, the data are nearly a
decade old, with signiﬁcant changes in practice pat-
terns and outcomes for STEMI patients over that
period. It emphasizes the importance of robust QoL
proforma prospectively applied to robust trials.
Studies enrolling STEMI patients with MVCAD are
challenging to design and conduct. Patients present
acutely ill with considerable heterogeneity regarding
myocardium at risk for both the culprit and nonculprit
vessels. The severity and complexity of the lesion and
comorbidities, such as renal disease, anemia, bleeding
risk, and left ventricular function, all inﬂuence com-
plex decision making. Additionally, it is not simply an
issue of culprit-only versus complete revasculariza-
tion; the timing of revascularization (same setting,
same hospital stay, or staged as an outpatient), and
presence or absence of ischemia (on the basis ofsymptoms, fractional ﬂow reserve, or stress testing)
require consideration. We thus are faced with impor-
tant variables making it challenging to study even
hard clinical endpoints in homogenous groups in a
randomized trial, let alone QoL in a registry; how do
you determine accurate prior baseline, for example, in
the acutely presenting patient? Further, the event it-
self will change QoL in a heterogeneous way irre-
spective of the effect of any therapeutic comparisons.
Clearly, QoL is important to patients and their
families after surviving an STEMI; yet, there are
almost no data regarding health status in STEMI pa-
tients with MVCAD. Actually, we have insufﬁcient
data regarding QoL or angina in most patients under-
going PCI, with the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug
Evaluation) trial being an exception (4). Therefore,
Jang et al. (3) are to be congratulated in trying to pin
down an important aspect of a difﬁcult strategic
consideration—if you undertake multivessel PCI at the
time of STEMI do the patients feel better? Although
the study is based on nonrandomized data (so the
selection criterion for who underwent multivessel
revascularization is uncertain), the paper provides
interesting food for thought. One of the most fasci-
nating results is the signiﬁcant practice variation
(from 0% to >70% revascularization at study sites).
This remarkable variation likely reﬂects our as yet lack
of robust evidence for this common but challenging
patient population. What this group has done well is
to highlight (again) that there is more to clinical
research studies than hard endpoints, with QoL often
felt to be “soft and unimportant”—something our pa-
tients (and families) would contest vigorously. Quality
assessment of clearly deﬁnedmarkers of QoL in robust
trials is imperative for the development of a holistic
management strategy. These results remind us this
should be an important goal for all clinical trials.
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